Regulus Therapeutics Inc (NASDAQ:RGLS) has a beta value of 0.37 and has seen 1.01 million shares traded in the recent trading session. The company, currently valued at $560.45M, closed the recent trade at $8.1 per share which meant it lost -$0.04 on the day or -0.55%% during that session. The RGLS stock price is -3.09% off its 52-week high price of $8.35 and 89.75% above the 52-week low of $0.83. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.09 million shares traded. The 3-month trading volume is 2.52 million shares.
The consensus among analysts is that Regulus Therapeutics Inc (RGLS) is Buy stock at the moment, with a recommendation rating of 2.67. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Regulus Therapeutics Inc (NASDAQ:RGLS) trade information
Sporting -0.55%% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RGLS stock price touched $8.1 or saw a rise of 2.29%. Year-to-date, Regulus Therapeutics Inc shares have moved 221.23%, while the 5-day performance has seen it change -1.52%. Over the past 30 days, the shares of Regulus Therapeutics Inc (NASDAQ:RGLS) have changed 2.34%. Short interest in the company has seen 2.09 million shares shorted with days to cover at 0.81.
Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could drop -15.71% from the levels at last check today.. The projected low price target is $7.0 while the price target rests at a high of $7.0. In that case, then, we find that the latest price level in today’s session is 13.58% off the targeted high while a plunge would see the stock lose 13.58% from the levels at last check today..
Regulus Therapeutics Inc (RGLS) estimates and forecasts
The company’s shares have gained 436.09% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 40.21% over the past 5 years. Earnings growth for 2025 is a modest -10.57% while over the next 5 years, the company’s earnings are expected to increase by 11.89%.
RGLS Dividends
Regulus Therapeutics Inc is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Regulus Therapeutics Inc (NASDAQ:RGLS)’s Major holders
Insiders own 2.71% of the company shares, while shares held by institutions stand at 82.87% with a share float percentage of 85.18%. Investors are also buoyed by the number of investors in a company, with Regulus Therapeutics Inc having a total of 98.0 institutions that hold shares in the company. The top two institutional holders are FEDERATED HERMES, INC. with over 12.85 million shares worth more than $22.94 million. As of 2024-06-30, FEDERATED HERMES, INC. held 19.9374% of shares outstanding.
The other major institutional holder is RA CAPITAL MANAGEMENT, L.P., with the holding of over 6.25 million shares as of 2024-06-30. The firm’s total holdings are worth over $11.16 million and represent 9.6952% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund and Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund . As of Jan 31, 2025 , the former fund manager holds about 11.38% shares in the company for having 7.88 shares of worth $63.8 million while later fund manager owns 7.42 shares of worth $60.04 million as of Jan 31, 2025 , which makes it owner of about 10.71% of company’s outstanding stock.
